Short treatment with sofosbuvir and ledipasvir over only 6 weeks is sufficient to cure acute hepatitis C (HCV)
A pilot study presented today found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a ‘short-duration’ of six weeks had undetectable HCV after a 12 week follow-up. The investigator-initiated study, presented at The International Liver CongressTM in Barcelona, Spain, demonstrated that the combination of sofosbuvir and ledipasvir for only six weeks is sufficient to treat patients with acute HCV.
Those infected with HCV usually develop acute Hepatitis C, which spontaneously clears in 10 to 50% of infected persons. Early diagnosis of HCV infection is rare and the disease may go unnoticed until patients have already developed serious liver damage.1 Sofosbuvir and ledipasvir is one possible regimen for treatment of patients with chronic HCV. Sustained virologic response (SVR) is greater than 95% with a 12-week course of this treatment.2
“Given the high cost of sofosbuvir and ledipasvir, and the associated side effects that occur during treatment, we set out to assess whether shortened treatment duration could be an effective option for acute Hepatitis C patients,” said Katja Deterding from Hannover Medical School, Germany and study author. “Our research demonstrates that not only is the combination of sofosbuvir and ledipasvir safe, well tolerated and effective in acute HCV genotype 1 patients who have severe liver disease with very high liver enzymes, but a shorter treatment duration does not appear to hinder efficacy,” confirmed Professor Heiner Wedemeyer, the senior author of this study.
The German pilot study, performed by the German HepNet Study-House included 20 patients. Risk factors of HCV infection among the study members included; sexual transmission (n=11), medical procedures/needle stick injury (n=5), drug use (n=1), and nail treatment complications (n=1). The causes were unspecified for the remaining two patients.
All 20 patients completed six weeks of sofosbuvir and ledipasvir without ribavirin. At the 12 week follow up, all 20 patients had undetectable HCV and achieved SVR (100%). Fatigue was the most frequent side effect reported by study members (30%).
“These exciting findings open up short and cost-effective treatment options that could prevent the spread of HCV in high risk populations,” said Professor Frank Tacke, EASL Governing Board member. “We look forward to seeing this pilot study extended so the findings can be validated and then hopefully used as a tool to change clinical practice for the better.”
Learn more: Scientists find a way to cure hepatitis C with 6 weeks of treatment
The Latest on: Hepatitis C
[google_news title=”” keyword=”Hepatitis C” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Hepatitis C
- JAMA: Early Treatment with Antivirals Effective in Children with Hepatitis Con April 28, 2024 at 7:00 am
A recent study published in the Journal of American Medical Association unveiled a promising findings regarding the efficacy and cost-effectiveness of early treatment for children with ...
- Tests And Crackdowns On Hepatitis Outbreaks Triggered By Outbreakson April 28, 2024 at 3:29 am
There has been an alarming increase in the number of hepatitis cases in Rawalpindi’s Fauji Colony area. To protect residents from the growing health threat, extensive awareness and testing initiatives ...
- U.S. Lags Behind Other Countries in Hepatitis-C Treatmenton April 28, 2024 at 3:00 am
A Biden initiative languishes without Congressional approval. By Ted Alcorn In the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave of new therapies have ...
- Hepatitis outbreak prompts crackdown, testing driveon April 28, 2024 at 12:44 am
This crackdown is part of a broader effort to enforce cleanliness protocols and mitigate the spread of hepatitis within the community. The prevalence of hepatitis in Fauji Colony has been alarming, ...
- Hepatitis C diagnosis 'like a death sentence'on April 27, 2024 at 12:46 am
A woman who contracted hepatitis C after being given contaminated blood during a transfusion more than 50 years ago says she feels like her life "has been stolen". Hazel Busby, 73, says the ordeal ...
- Canada Will Likely Miss WHO's Hepatitis C Elimination Targeton April 25, 2024 at 3:35 am
Canada is unlikely to meet the World Health Organization's (WHO's) target of eliminating the hepatitis C virus ( HCV) by 2030, research suggested. The elimination targets for HCV include an 80% ...
- Hepatitis Kills 3500 People Each Day, Says WHOon April 24, 2024 at 7:28 pm
Although annual incidence decreased from 2.5 million in 2019 to 2.2 million in 2022, the WHO considers it to be high.
- Global Hepatitis C Virus (HCV) Testing Industryon April 22, 2024 at 12:13 pm
The Global Hepatitis C Virus (HCV) Testing Industry is on a promising growth trajectory, fueled by increasing awareness and improved diagnostic tools. According to industry estimates, the market ...
- Canada's Hepatitis C Elimination Target Likely Out of Reachon April 17, 2024 at 11:36 am
Sole focus on screening and treatment may hinder experts from meeting the WHO's 2030 goal to eliminate hepatitis C virus (HCV).
- Viral hepatitis is a silent killer. It can’t be eliminated if it isn’t trackedon April 17, 2024 at 1:30 am
Before Covid emerged, viral hepatitis killed more people in the United States than all 60 other reportable infectious diseases combined.
via Bing News